The year in cardiovascular medicine 2021: valvular heart disease
█ Current opinion
Authors:
Helmut Baumgartner1, Bernard Iung2, David Messika-Zeitoun3, Catherine M. Otto4
1Department of Cardiology III – Adult Congenital and Valvular Heart Disease, University Hospital Muenster,
Germany
2Department of Cardiology, Bichat Hospital, APHP, Université de Paris, Paris, France
3Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada
4Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
Received 15 September 2021; revised 15 October 2021; accepted 23 December 2021;
online publish-ahead-of-print 3 January 2022
Introduction
The increasing burden of valvular heart disease (VHD) – in particular in an ageing population – is recognized by medical experts, although there is less awareness of these conditions by the general public and relevant stakeholders. Together with emerging non-surgical interventional treatment options, this has led to intense research interest in VHD with an enormous number of publications during the last year. Many of these publications address interventional treatment, including technical refinements and outcomes compared with surgery or medical therapy. In addition, attention has focused on pathophysiological aspects, improved diagnosis, risk stratification, and optimal timing for intervention. Importantly, new guidelines for the management of VHD have been published by both the ESC/EACTS and ACC/AHA (1, 2). This short overview can neither address all changes in the guidelines nor acknowledge all appreciable research efforts over this year. Thus, we have selected a few papers as examples that reflect the breadth of ongoing research, with the expectation that interested readers will find additional articles using online searches.
ISSUE: CARDIOLOGIA HUNGARICA | 2022 | VOLUME 52, ISSUE 1
click here to read the full article |
click here to read the pdf |